DNA X Inc (SONM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.03 is considered Undervalued compared with the five-year average of 1.89. The fair price of DNA X Inc (SONM) is between 22.88 to 72.40 according to relative valuation method. Compared to the current price of 5.43 USD , DNA X Inc By Undervalued By 76.27%.

Relative Value

Fair Zone

22.88-72.40

Current Price：5.43

76.27%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is DNA X Inc (SONM) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

DNA X Inc (SONM) has a current Price-to-Book (P/B) ratio of -4.17. Compared to its 3-year average P/B ratio of -1.22, the current P/B ratio is approximately 242.53% higher. Relative to its 5-year average P/B ratio of -0.11, the current P/B ratio is about 3711.20% higher. DNA X Inc (SONM) has a Forward Free Cash Flow (FCF) yield of approximately -607.51%. Compared to its 3-year average FCF yield of -79.86%, the current FCF yield is approximately 660.70% lower. Relative to its 5-year average FCF yield of -110.56%, the current FCF yield is about 449.50% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SONM competitors is 0.32, providing a benchmark for relative valuation. DNA X Inc Corp (SONM.O) exhibits a P/S ratio of 0.03, which is -89.83% above the industry average. Given its robust revenue growth of 7.94%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SONM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SONM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SONM currently overvalued or undervalued?

What is DNA X Inc (SONM) fair value?

SONM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of DNA X Inc (SONM) is between 22.88 to 72.40 according to relative valuation method.

How does SONM's valuation metrics compare to the industry average?

The average P/S ratio for SONM's competitors is 0.32, providing a benchmark for relative valuation. DNA X Inc Corp (SONM) exhibits a P/S ratio of 0.03, which is -89.83% above the industry average. Given its robust revenue growth of 7.94%, this premium appears unsustainable.

What is the current P/B ratio for DNA X Inc (SONM) as of Mar 02 2026?

As of Mar 02 2026, DNA X Inc (SONM) has a P/B ratio of -4.17. This indicates that the market values SONM at -4.17 times its book value.

What is the current FCF Yield for DNA X Inc (SONM) as of Mar 02 2026?

As of Mar 02 2026, DNA X Inc (SONM) has a FCF Yield of -607.51%. This means that for every dollar of DNA X Inc's market capitalization, the company generates -607.51 cents in free cash flow.

What is the current Forward P/E ratio for DNA X Inc (SONM) as of Mar 02 2026?

As of Mar 02 2026, DNA X Inc (SONM) has a Forward P/E ratio of 0.19. This means the market is willing to pay $0.19 for every dollar of DNA X Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for DNA X Inc (SONM) as of Mar 02 2026?

As of Mar 02 2026, DNA X Inc (SONM) has a Forward P/S ratio of 0.03. This means the market is valuing SONM at $0.03 for every dollar of expected revenue over the next 12 months.

SONM Valuation